스위스 -
이탈리아어 -
Swissmedic (Swiss Agency for Therapeutic Products)
ondansetron sandoz 4 mg/5 ml sirup
sandoz pharmaceuticals ag - ondansetronum - sirup - ondansetronum 4 mg ut ondansetroni hydrochloridum dihydricum, acidum citricum, natrii citras dihydricus, e 211 10 mg, sorbitolum 2.1 g ut sorbitolum liquidum non cristallisabile, aromatica (erdbeer) cum ethanolum 3 mg et alcohol benzylicus 3 µg, aqua purificata ad solutionem pro 5 ml corresp. natrium 4.3 mg. - antiemetico - synthetika
스위스 -
이탈리아어 -
Swissmedic (Swiss Agency for Therapeutic Products)
ondansetron accord 4 mg/2 ml konzentrat zur herstellung einer infusionslösung / injektionslösung
accord healthcare ag - ondansetronum - konzentrat zur herstellung einer infusionslösung / injektionslösung - ondansetronum 4 mg ut ondansetroni hydrochloridum dihydricum, natrii chloridum, natrii citras dihydricus, acidum citricum monohydricum, natrii hydroxidum, acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 2 ml corresp., natrium 7.27 mg. - antiemetico - synthetika
스위스 -
이탈리아어 -
Swissmedic (Swiss Agency for Therapeutic Products)
ondansetron accord 8 mg/4 ml konzentrat zur herstellung einer infusionslösung
accord healthcare ag - ondansetronum - konzentrat zur herstellung einer infusionslösung - ondansetronum 8 mg ut ondansetroni hydrochloridum dihydricum, natrii chloridum, natrii citras dihydricus, acidum citricum monohydricum, natrii hydroxidum, acidum hydrochloridum, aqua ad iniectabile, q.s. ad solutionem pro 4 ml corresp. natrium 14.53 mg. - antiemetico - synthetika
이탈리아 -
이탈리아어 -
Ministero della Salute
lbf master lifting foundation natural 30ml
lbf cosmetici srl -
이탈리아 -
이탈리아어 -
Ministero della Salute
lbf cosmetics master lifting foundation natural 01 fondotinta fluido 30ml
lbf cosmetics s.r.l. -
이탈리아 -
이탈리아어 -
Ministero della Salute
lbf cosmetics master lifting foundation amber 03 fondotinta fluido 30ml
lbf cosmetics s.r.l. -
이탈리아 -
이탈리아어 -
Ministero della Salute
lbf cosmetics master lifting foundation 02 honey fondotinta fluido 30ml
lbf cosmetics s.r.l. -
유럽 연합 -
이탈리아어 -
EMA (European Medicines Agency)
nyxthracis (previously obiltoxaximab sfl)
sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - sieri immuni e immunoglobuline, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.